AbbVie combines advanced science, expertise and passion to solve serious health issues and have a remarkable impact on people’s lives. Read through our press releases to see our latest efforts to improve patient care.

If you are a member of the news media and have questions or need additional information, please contact our Communications Team.

   Clear Filter

Jun 19, 2014

AbbVie Declares Quarterly Dividend

NORTH CHICAGO, Ill., June 19, 2014 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend of $0.42 per share. 

Jun 17, 2014

European Medicines Agency Validates Marketing Authorization Applications for AbbVie's Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 1 Chronic Hepatitis C

NORTH CHICAGO, Ill., June 17, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that the Marketing Authorization Applications (MAAs) for its investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection have been validated and are under accelerated assessment by the European Medicines Agency (EMA).

Jun 16, 2014

Biogen Idec and AbbVie Announce Positive Top-Line Results from Phase 3 Study Investigating Daclizumab High-Yield Process in Multiple Sclerosis

CAMBRIDGE, Mass. and NORTH CHICAGO, Ill. – June 16, 2014 – Today Biogen Idec (NASDAQ: BIIB) and AbbVie (NYSE:ABBV) announced positive top-line results from the Phase 3 DECIDE clinical trial, designed to evaluate the superiority of once-monthly, subcutaneous daclizumab high-yield process (DAC HYP) when compared to intramuscular  interferon beta-1a (IFN β-1a), as a potential treatment for relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis (MS). Results showed that DAC HYP was superior on the study’s primary endpoint, demonstrating a statistically significant 45 percent reduction in annualized relapse rate (ARR) compared to IFN β-1a (p<0.0001). 

Jun 13, 2014

U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 1 Chronic Hepatitis C

NORTH CHICAGO, Ill., June 13, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that the New Drug Application (NDA) for its investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection has been accepted by the U.S. Food and Drug Administration (FDA) and has been granted priority review.

Jun 11, 2014

AbbVie Presents Results from Large Global Study of Patient Attitudes and Adherence Across Six Chronic Inflammatory Diseases

PARIS, June 11, 2014 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced results from its multi-country ALIGN study, which shows that across six chronic immune-mediated inflammatory diseases (IMIDs), adherence to treatment was generally higher in patients being treated with TNF inhibitors compared to patients treated with conventional therapy. Furthermore, patients who were "accepting" toward their medication were more often adherent, compared to patients who were "ambivalent" toward their medication, as estimated from their responses to validated questionnaires. Results were presented today at the European League Against Rheumatism (EULAR) 2014 Congress in Paris.

Jun 10, 2014

AbbVie to Present at Goldman Sachs 35th Annual Global Healthcare Conference

NORTH CHICAGO, Ill., June 10, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 35th Annual Global Healthcare Conference on Wednesday, June 11, 2014. Bill Chase, executive vice president and chief financial officer, will take part in a question and answer session at 10:40 a.m. Central time.

Jun 03, 2014

AbbVie to Present at Jefferies 2014 Global Healthcare Conference

NORTH CHICAGO, Ill., June 3, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Jefferies 2014 Global Healthcare Conference on Wednesday, June 4, 2014. Scott Brun, M.D., vice president, pharmaceutical development, will take part in a question and answer session at 8:30 a.m. Central time.

Jun 03, 2014

AbbVie Opens Expanded Manufacturing Facility in Sligo, Ireland

-- €85 million investment creates greater manufacturing capacity to deliver new medicines for patients

May 31, 2014

AbbVie Presents New Results from Studies of Investigational Oncology Compound ABT-199/GDC-0199 at the 2014 American Society of Clinical Oncology Annual Meeting

NORTH CHICAGO, Ill., May 31, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) released interim results from a Phase Ib clinical trial of ABT-199/GDC-0199, an investigational B-cell lymphoma 2 (BCL-2) selective inhibitor, in combination with rituximab (Abstract 7013). Results showed an overall response rate (ORR) of 84 percent, in patients with relapsed/refractory chronic lymphocytic leukemia (CLL), the most common leukemia in the United States. These results were presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), May 30June 3 in Chicago.

May 30, 2014

AbbVie Presents Results from Study of Investigational Compound in Patients with Glioblastoma at the American Society of Clinical Oncology's 50th Annual Meeting

NORTH CHICAGO, Ill., May 30, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) released preliminary results from an ongoing Phase I study with ABT-414, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody drug conjugate, in combination with temozolomide, which showed four objective responses, including one complete response, in patients with recurrent or unresectable glioblastoma multiforme. Specifically, one patient experienced a complete response (CR) and three patients experienced partial responses (PR) as measured with the Revised Assessment in Neuro-Oncology (RANO) criteria. These results were presented for the first time at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), May 30June 3 in Chicago.